Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 27
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
MiNK Therapeutics Inc
INKT
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$10.43
-0.28
-2.61%
Dern. MÀJ: Oct 26, 8:17 AM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
MiNK Therapeutics Financials
MiNK Therapeutics (INKT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 41.51 percent increase over losses of $(1.06) per share
Benzinga Newsdesk
PRO
MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.78) by 26.92 percent. This is a 18.57 percent increase over losses of $(0.70) per share from
Benzinga Newsdesk
Earnings Scheduled For May 15, 2026
Benzinga Insights
PRO
MiNK Therapeutics Q4 EPS $(0.56) Beats $(0.82) Estimate
Benzinga Newsdesk
Earnings Scheduled For March 31, 2026
Benzinga Insights
PRO
MiNK Therapeutics Q3 EPS $(0.65) Misses $(0.61) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.61) by 5.69 percent. This is a 41.3 percent decrease over losses of $(0.46) per share from
Benzinga Newsdesk
